Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Guselkumab bei pädiatrischen Teilnehmern mit mittelschwerem bis schwerem aktivem Morbus Crohn (MACARONI-23)

2. November 2026 aktualisiert von: Janssen Research & Development, LLC

Eine multizentrische, randomisierte Phase-3-Plattformstudie zur p19-Hemmung des IL-23-Signalwegs zur Feststellung der Wirksamkeit bei pädiatrischem Morbus Crohn

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

120

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Nedlands, Australien, 6009
        • Rekrutierung
        • Perth Children's Hospital
      • South Brisbane, Australien, 4101
        • Rekrutierung
        • Mater Hospital Brisbane
      • Westmead, Australien, 2145
        • Rekrutierung
        • The Children's Hospital at Westmead
      • Brussels, Belgien, 1090
        • Rekrutierung
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgien, 1200
        • Rekrutierung
        • Cliniques Universitaires Saint Luc
      • Ghent, Belgien, 9000
        • Rekrutierung
        • Universitair Ziekenhuis Gent
      • Leuven, Belgien, 3000
        • Rekrutierung
        • UZ Leuven
      • Campinas, Brasilien, 13060-904
        • Rekrutierung
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brasilien, 80250-060
        • Rekrutierung
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brasilien, 74605-020
        • Rekrutierung
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brasilien, 90035-074
        • Rekrutierung
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasilien, 90035-007
        • Rekrutierung
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brasilien, 29040-091
        • Rekrutierung
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brasilien, 100000
        • Rekrutierung
        • INTEGRAL Pesquisa e Ensino
      • Amiens, Frankreich, 80054
        • Rekrutierung
        • CHU Amiens-Hopital Nord
      • Lille, Frankreich, 59037
        • Rekrutierung
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, Frankreich, 75019
        • Rekrutierung
        • Hôpital Robert Debré
      • Paris, Frankreich, 75015
        • Rekrutierung
        • Hôpital Necker - Enfants Malades
      • Beersheba, Israel, 84101
        • Rekrutierung
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israel, 70300
        • Rekrutierung
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israel, 9103102
        • Rekrutierung
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9124001
        • Rekrutierung
        • Hadassah Medical Center
      • Petah Tikva, Israel, 4920235
        • Rekrutierung
        • Schneider Children's Medical Center
      • Rehovot, Israel, 761001
        • Rekrutierung
        • Kaplan Medical Center
      • Alessandria, Italien, 15121
        • Rekrutierung
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Italien, 24127
        • Rekrutierung
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Italien, 40124
        • Rekrutierung
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Italien, 50139
        • Rekrutierung
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Italien, 20154
        • Rekrutierung
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Italien, 161
        • Rekrutierung
        • AOU Policlinico Umberto I
      • Hirosaki, Japan, 036-8563
        • Rekrutierung
        • Hirosaki University Hospital
      • Kagoshima, Japan, 890-8544
        • Rekrutierung
        • Kagoshima University Hospital
      • Kashiwa-shi, Japan, 277-0871
        • Rekrutierung
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japan, 650 0017
        • Rekrutierung
        • Kobe University Hospital
      • Saga, Japan, 849-8501
        • Rekrutierung
        • Saga University Hospital
      • Sendai, Japan, 989-3126
        • Rekrutierung
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japan, 157 8535
        • Rekrutierung
        • National Center for Child Health and Development
      • Tokyo, Japan, 113-8431
        • Rekrutierung
        • Juntendo University Hospital
      • Tsu, Japan, 514 8507
        • Rekrutierung
        • Mie University Hospital
      • Ube, Japan, 755-8505
        • Rekrutierung
        • Yamaguchi University Hospital
      • Yokohama, Japan, 232-0024
        • Rekrutierung
        • Yokohama City University Medical Center
      • Yokohama, Japan, 230-8765
        • Rekrutierung
        • Saiseikai Yokohamashi Tobu Hospital
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 6R8
        • Rekrutierung
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • Rekrutierung
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Kanada, M5G 1X8
        • Rekrutierung
        • Hospital For Sick Children
      • Rotterdam, Niederlande, 3015 GD
        • Rekrutierung
        • Erasmus Medisch Centrum
      • Nordbyhagen, Norwegen, 1474
        • Rekrutierung
        • Akershus Universitetssykehus HF
      • Oslo, Norwegen, 424
        • Rekrutierung
        • Oslo University Hospital
      • Tromsø, Norwegen, 9038
        • Rekrutierung
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Norwegen, 7030
        • Rekrutierung
        • St. Olavs Hospital
      • Rzeszów, Polen, 35-302
        • Rekrutierung
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • Rekrutierung
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Rekrutierung
        • Instytut Pomnik Centrum Zdrowia
      • Braga, Portugal, 4710-243
        • Rekrutierung
        • Hospital de Braga
      • Lisbon, Portugal, 1649-035
        • Rekrutierung
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Portugal, 4200-319
        • Rekrutierung
        • Centro Hospitalar de Sao Joao E.P.E.
      • Córdoba, Spanien, 14004
        • Rekrutierung
        • Hosp Reina Sofia
      • Sabadell, Spanien, 8208
        • Rekrutierung
        • Corporacio Sanitari Parc Tauli
      • Valencia, Spanien, 46026
        • Rekrutierung
        • Hosp. Univ. I Politecni La Fe
      • Busan, Südkorea, 48108
        • Rekrutierung
        • Inje University Haeundae Paik Hospital
      • Daegu, Südkorea, 41404
        • Rekrutierung
        • Kyungpook National University Chilgok Hospital
      • Seoul, Südkorea, 03080
        • Rekrutierung
        • Seoul National University Hospital
      • Seoul, Südkorea, 06351
        • Rekrutierung
        • Samsung Medical Center
      • Seoul, Südkorea, 120-752
        • Rekrutierung
        • Severance Hospital Yonsei University Health System
    • California
      • Los Angeles, California, Vereinigte Staaten, 90048
        • Rekrutierung
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, Vereinigte Staaten, 06106
        • Rekrutierung
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Rekrutierung
        • Emory University
      • Atlanta, Georgia, Vereinigte Staaten, 30342
        • Rekrutierung
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202-5225
        • Rekrutierung
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Rekrutierung
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, Vereinigte Staaten, 07960
        • Rekrutierung
        • Goryeb Children's Hospital
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • Rekrutierung
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Vereinigte Staaten, 10032
        • Rekrutierung
        • Columbia University Medical Center
      • New York, New York, Vereinigte Staaten, 10021-5663
        • Rekrutierung
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, Vereinigte Staaten, 45404
        • Rekrutierung
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, Vereinigte Staaten, 76104
        • Rekrutierung
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, Vereinigte Staaten, 05446
        • Rekrutierung
        • University of Vermont Medical Center
      • Glasgow, Vereinigtes Königreich, G51 4TF
        • Rekrutierung
        • Royal Hospital for Sick Children
      • London, Vereinigtes Königreich, WC1N 3JH
        • Rekrutierung
        • Great Ormond Street Hospital
      • Manchester, Vereinigtes Königreich, M13 9WL
        • Rekrutierung
        • Royal Manchester Children's Hospital
      • Manchester, Vereinigtes Königreich, M13 9WL
        • Rekrutierung
        • Nowgen Centre, Research and Innovation
      • Oxford, Vereinigtes Königreich, OX3 9DU
        • Rekrutierung
        • John Radcliffe Hospital
      • Sheffield, Vereinigtes Königreich, S10 2TH
        • Rekrutierung
        • Sheffield Children's Hospital
      • Vienna, Österreich, 1090
        • Rekrutierung
        • AKH - Medizinische Universitat Wien

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre bis 17 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Guselkumab will be administered intravenously.

Andere Namen:
  • CNTO1959
  • TREMFJA
Experimental: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Guselkumab will be administered intravenously.

Andere Namen:
  • CNTO1959
  • TREMFJA
Experimental: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Guselkumab will be administered intravenously.

Andere Namen:
  • CNTO1959
  • TREMFJA
Experimental: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Guselkumab will be administered intravenously.

Andere Namen:
  • CNTO1959
  • TREMFJA
Experimental: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Guselkumab will be administered intravenously.

Andere Namen:
  • CNTO1959
  • TREMFJA

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants with Clinical Remission at Week 52
Zeitfenster: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Zeitfenster: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants with Clinical Response at Week 12
Zeitfenster: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Zeitfenster: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Zeitfenster: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Zeitfenster: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Zeitfenster: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Zeitfenster: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Zeitfenster: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Zeitfenster: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Zeitfenster: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Zeitfenster: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Zeitfenster: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Zeitfenster: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Clinical Trial, Janssen Research & Development, LLC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. März 2024

Primärer Abschluss (Geschätzt)

27. Oktober 2027

Studienabschluss (Geschätzt)

14. August 2028

Studienanmeldedaten

Zuerst eingereicht

20. Juni 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Juni 2023

Zuerst gepostet (Tatsächlich)

28. Juni 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CR109212
  • 2021-006282-37 (EudraCT-Nummer)
  • CNTO1959PBCRD3007 (Andere Kennung: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Registrierungskennung: EUCT number)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .